Envestnet Asset Management Inc. Sells 19,420 Shares of Hologic, Inc. (HOLX)
Envestnet Asset Management Inc. decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 16.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 98,149 shares of the medical equipment provider’s stock after selling 19,420 shares during the period. Envestnet Asset Management Inc.’s holdings in Hologic were worth $3,601,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in HOLX. Parnassus Investments CA acquired a new position in shares of Hologic in the 3rd quarter valued at $277,062,000. Capital World Investors acquired a new position in shares of Hologic during the 2nd quarter valued at $312,441,000. HealthCor Management L.P. acquired a new position in shares of Hologic during the 2nd quarter valued at $76,604,000. Columbus Circle Investors acquired a new position in shares of Hologic during the 2nd quarter valued at $54,511,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Hologic by 4.2% during the 2nd quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock valued at $1,340,850,000 after acquiring an additional 1,200,825 shares in the last quarter. Institutional investors and hedge funds own 98.08% of the company’s stock.
In other news, Director Elaine Ullian sold 9,282 shares of the firm’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $40.50, for a total value of $375,921.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Lawrence M. Levy sold 9,596 shares of Hologic stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total transaction of $353,228.76. The disclosure for this sale can be found here. Insiders sold a total of 28,833 shares of company stock worth $1,107,270 in the last ninety days. Insiders own 0.79% of the company’s stock.
A number of research analysts have issued reports on HOLX shares. Royal Bank of Canada reissued a “hold” rating and set a $42.00 target price on shares of Hologic in a research note on Friday, September 22nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $50.00 price target on shares of Hologic in a research note on Monday, October 2nd. Zacks Investment Research lowered shares of Hologic from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $45.00 price target (down from $48.00) on shares of Hologic in a research note on Monday, October 9th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $44.00 price target (down from $49.00) on shares of Hologic in a research note on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $47.86.
Shares of Hologic, Inc. (NASDAQ:HOLX) opened at $43.82 on Tuesday. The stock has a market cap of $11,768.93, a PE ratio of 21.13, a P/E/G ratio of 2.06 and a beta of 0.95. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79. Hologic, Inc. has a 1 year low of $35.76 and a 1 year high of $46.80.
Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.01. The company had revenue of $802.90 million for the quarter, compared to analyst estimates of $792.54 million. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.52 EPS. analysts expect that Hologic, Inc. will post 2.12 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Envestnet Asset Management Inc. Sells 19,420 Shares of Hologic, Inc. (HOLX)” was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.watchlistnews.com/envestnet-asset-management-inc-sells-19420-shares-of-hologic-inc-holx/1758975.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.